RecruitingPhase 3NCT06585787
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Sponsor
Karuna Therapeutics
Enrollment
406 participants
Start Date
Sep 26, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
Eligibility
Min Age: 55 YearsMax Age: 90 Years
Inclusion Criteria4
- Patients who are 55 to 90 years of age, inclusive, at the time of Screening (Visit 1).
- Patients who are diagnosed with AD based on the 2024 revised criteria for diagnosis and staging of AD: Alzheimer's Association Workgroup.
- Patient must have a magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain (completed within the past 5 years) taken during or subsequent to the onset of dementia to rule out other central nervous system (CNS) disease that could account for the dementia syndrome, eg, major stroke, neoplasm, subdural hematoma.
- Patient must have a history of psychotic symptoms (meeting International Psychogeriatric Association criteria) for at least 2 months prior to Screening (Visit 1) (participants may or may not have symptoms of agitation).
Exclusion Criteria4
- \- Patients will not be able to participate if they have:
- i) Psychotic symptoms that are primarily attributable to a condition other than the AD causing the dementia, eg, schizophrenia, schizoaffective disorder, delusional disorder, or mood disorder with psychotic features.
- ii) History of major depressive episode with psychotic features during the 12 months prior to Screening, or history of bipolar disorder, schizophrenia, or schizoaffective disorder.
- iii) Patients are not able to participate if they have certain safety concerns, including certain laboratory test irregularities.
Interventions
DRUGKarXT
Specified dose on specified days
DRUGPlacebo
Specified dose on specified days
Locations(278)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06585787
Related Trials
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT064675391 location
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229241 locations
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
NCT071782101 location
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT041233141 location
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
NCT0629759010 locations